These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
533 related articles for article (PubMed ID: 19194470)
21. Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia. Carraway HE; Malkaram SA; Cen Y; Shatnawi A; Fan J; Ali HEA; Abd Elmageed ZY; Buttolph T; Denvir J; Primerano DA; Fandy TE Sci Rep; 2020 Jun; 10(1):10325. PubMed ID: 32587297 [TBL] [Abstract][Full Text] [Related]
22. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739 [TBL] [Abstract][Full Text] [Related]
23. DNA methylation and gene silencing in cancer. Baylin SB Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S4-11. PubMed ID: 16341240 [TBL] [Abstract][Full Text] [Related]
24. DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status. Nakamura K; Nakabayashi K; Htet Aung K; Aizawa K; Hori N; Yamauchi J; Hata K; Tanoue A PLoS One; 2015; 10(3):e0120545. PubMed ID: 25799509 [TBL] [Abstract][Full Text] [Related]
25. Decitabine. Daskalakis M; Blagitko-Dorfs N; Hackanson B Recent Results Cancer Res; 2010; 184():131-57. PubMed ID: 20072836 [TBL] [Abstract][Full Text] [Related]
26. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. Berg T; Guo Y; Abdelkarim M; Fliegauf M; Lübbert M Leuk Res; 2007 Apr; 31(4):497-506. PubMed ID: 17056112 [TBL] [Abstract][Full Text] [Related]
27. Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells. Tsujioka T; Yokoi A; Itano Y; Takahashi K; Ouchida M; Okamoto S; Kondo T; Suemori S; Tohyama Y; Tohyama K Sci Rep; 2015 Nov; 5():16709. PubMed ID: 26577244 [TBL] [Abstract][Full Text] [Related]
28. Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells. Nishioka C; Ikezoe T; Yang J; Udaka K; Yokoyama A Leuk Res; 2011 Jul; 35(7):932-9. PubMed ID: 21550660 [TBL] [Abstract][Full Text] [Related]
29. Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3. Buchi F; Masala E; Rossi A; Valencia A; Spinelli E; Sanna A; Gozzini A; Santini V Epigenetics; 2014 Mar; 9(3):387-95. PubMed ID: 24300456 [TBL] [Abstract][Full Text] [Related]
30. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia. Momparler RL; Côté S; Eliopoulos N Leukemia; 1997 Mar; 11 Suppl 1():S1-6. PubMed ID: 9130684 [TBL] [Abstract][Full Text] [Related]
31. 5-azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation. Füller M; Klein M; Schmidt E; Rohde C; Göllner S; Schulze I; Qianli J; Berdel WE; Edemir B; Müller-Tidow C; Tschanter P Int J Oncol; 2015 Mar; 46(3):1192-204. PubMed ID: 25501798 [TBL] [Abstract][Full Text] [Related]
32. The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells. Hummel-Eisenbeiss J; Hascher A; Hals PA; Sandvold ML; Müller-Tidow C; Lyko F; Rius M Mol Pharmacol; 2013 Sep; 84(3):438-50. PubMed ID: 23814180 [TBL] [Abstract][Full Text] [Related]
33. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Stresemann C; Lyko F Int J Cancer; 2008 Jul; 123(1):8-13. PubMed ID: 18425818 [TBL] [Abstract][Full Text] [Related]
34. The euphoria of hypomethylating agents in MDS and AML: is it justified? Sekeres MA Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of dna methylation by 5-aza-2'-deoxycytidine correlates with induction of K562 cells differentiation. Fabianowska-Majewska K; Wyczechowska D; Czyz M Adv Exp Med Biol; 2000; 486():343-7. PubMed ID: 11783512 [No Abstract] [Full Text] [Related]
36. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. Hollenbach PW; Nguyen AN; Brady H; Williams M; Ning Y; Richard N; Krushel L; Aukerman SL; Heise C; MacBeth KJ PLoS One; 2010 Feb; 5(2):e9001. PubMed ID: 20126405 [TBL] [Abstract][Full Text] [Related]
37. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection. Issa JP Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S24-9. PubMed ID: 16341237 [TBL] [Abstract][Full Text] [Related]
38. Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia. Lainey E; Wolfromm A; Marie N; Enot D; Scoazec M; Bouteloup C; Leroy C; Micol JB; De Botton S; Galluzzi L; Fenaux P; Kroemer G Oncogene; 2013 Sep; 32(37):4331-42. PubMed ID: 23085751 [TBL] [Abstract][Full Text] [Related]
39. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia. Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556 [TBL] [Abstract][Full Text] [Related]
40. Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors. Arimany-Nardi C; Errasti-Murugarren E; Minuesa G; Martinez-Picado J; Gorboulev V; Koepsell H; Pastor-Anglada M Br J Pharmacol; 2014 Aug; 171(16):3868-80. PubMed ID: 24780098 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]